Tiotropium bromide is effective for severe asthma with noneosinophilic phenotype

Download figure
Open in new tab
Download powerpoint
Fig. 1—
Spearman rank correlations (r_S) between the change in forced expiratory volume in one second (ΔFEV₁) after 4 weeks of tiotropium bromide administration and a) eosinophil percentages or b) neutrophil percentages in induced sputum. Eosinophil and neutrophil percentages were determined prior to tiotropium bromide administration. In all subjects a) r_S = -0.669, p = 0.003 and b) r_S = 0.540, p = 0.025. In smokers a) r_S = -0.706, p = 0.034 and b) r_S = 0.361, p = 0.339. In nonsmokers a) r_S = -0.762, p = 0.028 and b) r_S = 0.762, p = 0.028. ○: smokers; •: nonsmokers.

Table 1—

Subject characteristics

Subjects n	17
Males n	7
Age yrs	61.0±11.5 (45–78)
BMI kg·m⁻²	23.7±3.3
Smoking history n
Never-smoker	8
Ex-smoker	5
Current smoker	4
Atopy	9 (52.9)
Disease duration yrs	22.2±16.6
Asthma control test score	18.4±4.3
Anti-asthmatic drugs use
Inhaled corticosteroid	17 (100)
Oral corticosteroid	4 (23.5)
LABA	11 (64.7)
Theophylline	6 (35.3)
Leukotriene receptor antagonist	11 (64.7)
FVC L	2.83±0.80
FEV₁ L	1.68±0.69

Data are presented as mean±sd (range), mean±sd or n (%), unless otherwise stated. BMI: body mass index; LABA: long-acting β₂-agonist; FVC: forced vital capacity; FEV₁: forced expiratory volume in one second.